HANDOK Inc.

A002390

KR7002390003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
13,710 ^KRW	-0.44%		-0.29%	-4.13%

Apr. 16	Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	MT
Apr. 15	Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	CI

HANDOK Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 01:55 am EDT

HANDOK Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 8,960.17 million compared to KRW 7,934.56 million a year ago. Net loss was KRW 4,349.7 million compared to net income of KRW 343.67 million a year ago.

Basic loss per share from continuing operations was KRW 316 compared to basic earnings per share from continuing operations of KRW 25 a year ago. Basic loss per share was KRW 316 compared to basic earnings per share of KRW 25 a year ago.

Latest news about HANDOK Inc.

Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	Apr. 15	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	Apr. 14	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	Feb. 13	MT
HANDOK Inc.(KOSE:A002390) dropped from S&P Global BMI Index	23-09-18	CI
HANDOK Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Rezolute Unveils Plans for Secondary Offering of 3.24 Million Shares	22-10-28	MT
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency	22-06-14	MT
AUM Biosciences Enters in A Strategic Collaboration with Handok and CMG Pharm to Develop ‘CHC2014’, New Pan-TRK Inhibitor for Cancer Treatment	21-05-11	CI
WELT Corp., Ltd announced that it has received KRW 6 billion in funding from HANDOK Inc., Smilegate Investment, Inc., POSCO Venture Capital Co., Ltd.	21-03-24	CI
Adicet Bio, Inc. announced that it has received $80 million in funding from a group of investors	19-10-01	CI
Rezolute, Inc. announced that it has received $24.05 million in funding from Genexine, Inc., Handok, Inc., District 2 Capital Fund LP, The Bigger Capital Fund, LP and another investor	19-08-11	CI
Adicet Bio, Inc. announced that it expects to receive $80 million in funding	19-07-24	CI
Rezolute, Inc. announced that it expects to receive $20.25 million in funding from District 2 Capital Fund LP, The Bigger Capital Fund, LP, Genexine, Inc., Handok, Inc.	19-07-22	CI
TRIGR Therapeutics, Inc announced that it has received $14 million in funding from Handok Inc.	19-03-24	CI
BiomX Ltd announced that it has received $32 million in funding from a group of investors	19-02-19	CI
Rezolute, Inc. announced that it has received $25 million in funding from Genexine, Inc., Handok, Inc.	19-01-29	CI
Rezolute, Inc. announced that it expects to receive $25 million in funding from Genexine, Inc., Handok Inc.	19-01-06	CI
An unknown buyer cancelled the acquisition of 2.7% stake in Genexine, Inc. from Handok Inc..	18-12-19	CI
Handok Hires Cho Jeong-yol to replace Kim Chul-joon as President	18-09-05	CI
TRIGR Therapeutics, Inc announced that it expects to receive $9 million in funding from Handok Inc.	18-07-30	CI
An unknown buyer agreed to acquire 2.7% stake in Genexine, Inc. from Handok Inc. for KRW 27.3 billion.	17-12-20	CI
Handok Inc.(KOSE:A002390) added to S&P Global BMI Index	15-09-21	CI
Institutional investors acquired 1.99% stake in Handok Inc. from Paean, Inc. for KRW 10 billion.	15-07-07	CI
Institutional investors acquired 2.38% stake in Handok Inc. from Paean, Inc. for KRW 9 billion.	15-04-27	CI
Handok Inc. cancelled the acquisition of an additional 16% stake in Genexine, Inc..	15-03-24	CI

Chart HANDOK Inc.

Duration

Period

More charts

Company Profile

HANDOK Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company's products include Amaryl for diabetes; Tritace for hypertension, myocardial infarction, heart failure and other cardiovascular diseases; Teveten and Triapin for essential hypertension; Munobal for hypertension and stenocardia; Ketas for disturbance of cerebral circulation; Lasix for hypertension and edema, and remedies for skin and others. It also provides over-the-counter (OTC) pharmaceuticals, healthcare products, as well as medical devices, diagnostic reagents and vaccines. In addition, the Company is involved in the real estates rental business. On July 26, 2013, it changed its name to HANDOK Inc. from Handok Pharmaceuticals Co., LTD.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HANDOK INC.	-4.13%	139M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

HANDOK Inc.

Equities

A002390

KR7002390003

Pharmaceuticals

HANDOK Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

Latest news about HANDOK Inc.

Chart HANDOK Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals